308 related articles for article (PubMed ID: 19949981)
21. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model.
Guo N; Lang L; Gao H; Niu G; Kiesewetter DO; Xie Q; Chen X
Mol Imaging Biol; 2012 Dec; 14(6):743-52. PubMed ID: 22437879
[TBL] [Abstract][Full Text] [Related]
23. 18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging.
Hu K; Tang X; Tang G; Yao S; Yao B; Wang H; Nie D; Liang X; Tang C; He S
PLoS One; 2015; 10(9):e0138675. PubMed ID: 26397833
[TBL] [Abstract][Full Text] [Related]
24. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression.
Li ZB; Wu Z; Chen K; Chin FT; Chen X
Bioconjug Chem; 2007; 18(6):1987-94. PubMed ID: 18030991
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice.
Laitinen I; Saraste A; Weidl E; Poethko T; Weber AW; Nekolla SG; Leppänen P; Ylä-Herttuala S; Hölzlwimmer G; Walch A; Esposito I; Wester HJ; Knuuti J; Schwaiger M
Circ Cardiovasc Imaging; 2009 Jul; 2(4):331-8. PubMed ID: 19808614
[TBL] [Abstract][Full Text] [Related]
26. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
Beer AJ; Lorenzen S; Metz S; Herrmann K; Watzlowik P; Wester HJ; Peschel C; Lordick F; Schwaiger M
J Nucl Med; 2008 Jan; 49(1):22-9. PubMed ID: 18077538
[TBL] [Abstract][Full Text] [Related]
27. (64)Cu labeled AmBaSar-RGD2 for micro-PET imaging of integrin αvβ3 expression.
Cai H; Li Z; Huang CW; Park R; Conti PS
Curr Radiopharm; 2011 Jan; 4(1):68-74. PubMed ID: 22191616
[TBL] [Abstract][Full Text] [Related]
28. (18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors.
Ma Y; Liang S; Guo J; Guo R; Wang H
J Labelled Comp Radiopharm; 2014 Sep; 57(11):627-31. PubMed ID: 25294311
[TBL] [Abstract][Full Text] [Related]
29. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
30. Imaging integrin αvβ 3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe.
Wu H; Chen H; Pan D; Ma Y; Liang S; Wan Y; Fang Y
Mol Imaging Biol; 2014 Dec; 16(6):781-92. PubMed ID: 25001194
[TBL] [Abstract][Full Text] [Related]
31. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.
Dijkgraaf I; Terry SY; McBride WJ; Goldenberg DM; Laverman P; Franssen GM; Oyen WJ; Boerman OC
Contrast Media Mol Imaging; 2013; 8(3):238-45. PubMed ID: 23606427
[TBL] [Abstract][Full Text] [Related]
32. In Vivo Characterization of 4
Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
[TBL] [Abstract][Full Text] [Related]
33. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.
Liu Z; Yan Y; Chin FT; Wang F; Chen X
J Med Chem; 2009 Jan; 52(2):425-32. PubMed ID: 19113865
[TBL] [Abstract][Full Text] [Related]
34. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice.
Lang L; Li W; Guo N; Ma Y; Zhu L; Kiesewetter DO; Shen B; Niu G; Chen X
Bioconjug Chem; 2011 Dec; 22(12):2415-22. PubMed ID: 22026940
[TBL] [Abstract][Full Text] [Related]
35. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.
Zhang X; Xiong Z; Wu Y; Cai W; Tseng JR; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):113-21. PubMed ID: 16391195
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.
Beer AJ; Haubner R; Goebel M; Luderschmidt S; Spilker ME; Wester HJ; Weber WA; Schwaiger M
J Nucl Med; 2005 Aug; 46(8):1333-41. PubMed ID: 16085591
[TBL] [Abstract][Full Text] [Related]
37. First experience with clinical-grade ([18F]FPP(RGD₂): an automated multi-step radiosynthesis for clinical PET studies.
Chin FT; Shen B; Liu S; Berganos RA; Chang E; Mittra E; Chen X; Gambhir SS
Mol Imaging Biol; 2012 Feb; 14(1):88-95. PubMed ID: 21400112
[TBL] [Abstract][Full Text] [Related]
38. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
